# Head and Neck Cancer Studies

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/head-and-neck-cancer-studies/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the epidemiology, treatment, and prognosis of head and neck cancer, with a particular emphasis on human papillomavirus (HPV)-related oropharyngeal cancer. It covers topics such as the impact of HPV infection, the role of radiotherapy and chemotherapy, survival outcomes, and the molecular landscape of head and neck squamous cell carcinomas. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10307 |
| Works | 511 |

## Topic papers all

Showing 15 of 511.

- [Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer](https://scholariq.org/papers/human-papillomavirus-and-survival-of-patients-with-oropharyngeal-cancer/)
- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer](https://scholariq.org/papers/concurrent-chemotherapy-and-radiotherapy-for-organ-preservation-in-advanced/)
- [Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial](https://scholariq.org/papers/neoadjuvant-chemoradiotherapy-plus-surgery-versus-surgery-alone-for-oesophageal/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Genetic progression model for head and neck cancer: implications for field cancerization.](https://scholariq.org/papers/genetic-progression-model-for-head-and-neck-cancer-implications-for-field/)
- [Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781](https://scholariq.org/papers/phase-iii-trial-of-trimodality-therapy-with-cisplatin-fluorouracil-radiotherapy/)
- [INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy](https://scholariq.org/papers/int-0123-radiation-therapy-oncology-group-94-05-phase-iii-trial-of-combined/)
- [Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis](https://scholariq.org/papers/alcohol-consumption-and-site-specific-cancer-risk-a-comprehensive-dose-response/)
- [The Enigmatic Epidemiology of Nasopharyngeal Carcinoma](https://scholariq.org/papers/the-enigmatic-epidemiology-of-nasopharyngeal-carcinoma/)
- [Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer](https://scholariq.org/papers/long-term-results-of-rtog-91-11-a-comparison-of-three-nonsurgical-treatment/)
- [Head and Neck Cancer](https://scholariq.org/papers/head-and-neck-cancer/)
- [Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer](https://scholariq.org/papers/randomized-phase-iii-keynote-181-study-of-pembrolizumab-versus-chemotherapy-in/)
- [Carcinogenic human papillomavirus infection](https://scholariq.org/papers/carcinogenic-human-papillomavirus-infection/)

## Topic primary papers

Showing 15 of 233.

- [Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer](https://scholariq.org/papers/human-papillomavirus-and-survival-of-patients-with-oropharyngeal-cancer/)
- [Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck](https://scholariq.org/papers/nivolumab-for-recurrent-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for/)
- [Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer](https://scholariq.org/papers/concurrent-chemotherapy-and-radiotherapy-for-organ-preservation-in-advanced/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Genetic progression model for head and neck cancer: implications for field cancerization.](https://scholariq.org/papers/genetic-progression-model-for-head-and-neck-cancer-implications-for-field/)
- [Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer](https://scholariq.org/papers/long-term-results-of-rtog-91-11-a-comparison-of-three-nonsurgical-treatment/)
- [Head and Neck Cancer](https://scholariq.org/papers/head-and-neck-cancer/)
- [Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma](https://scholariq.org/papers/gemcitabine-and-cisplatin-induction-chemotherapy-in-nasopharyngeal-carcinoma/)
- [Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database](https://scholariq.org/papers/trends-in-incidence-and-prognosis-for-head-and-neck-cancer-in-the-united-states/)
- [Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines](https://scholariq.org/papers/delineation-of-the-neck-node-levels-for-head-and-neck-tumors-a-2013-update/)
- [Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis](https://scholariq.org/papers/chemotherapy-and-radiotherapy-in-nasopharyngeal-carcinoma-an-update-of-the-mac/)
- [Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225](https://scholariq.org/papers/intensity-modulated-radiation-therapy-with-or-without-chemotherapy-for/)
- [CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines](https://scholariq.org/papers/ct-based-delineation-of-organs-at-risk-in-the-head-and-neck-region-dahanca-eortc/)
- [Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety](https://scholariq.org/papers/randomized-trial-of-radiotherapy-versus-concurrent-chemoradiotherapy-followed-by/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.